Le Lézard
Classified in: Health, Science and technology
Subjects: Webcast, Business Update

Bruker Corporation to Host Investor Webinar on May 17, 2024


Bruker Corporation (Nasdaq: BRKR) today announced it intends to hold an Investor Webinar from 10 am to about 12 noon Eastern Daylight Time (EDT) on May 17, 2024, to provide additional insights into its three recent acquisitions of Chemspeed, ELITech, and of the NanoString business. Bruker also expects to provide an update to its medium-term financial outlook.

The Investor Webinar will include presentations by CEO Frank H. Laukien, CFO Gerald Herman, and by the leaders of these three new Bruker businesses, all followed by a live Q&A session for analysts and investors.

A link to the Investor Webinar will be available in the Events & Presentations section of the Company's Investor Relations website at https://ir.bruker.com. A replay will be available on Bruker's Investor Relations website after the conclusion of the event.

About Bruker Corporation ? Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.


These press releases may also interest you

at 08:05
Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced additional favorable safety and efficacy data from the company's ongoing Phase 1b/2 clinical trial...

at 08:05
Xcell Biosciences Inc. (Xcellbio), an innovative technology company focused on cell and gene therapy manufacturing applications, and AmplifyBio, a rapidly growing contract development and manufacturing organization, today announced the launch of a...

at 08:05
GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois...

at 08:05
Kiromic BioPharma, Inc. ("Kiromic" or the "Company") announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltaceltm (KB-GDT-01), Kiromic's allogeneic,...

at 08:03
JPMA Cares, the nonprofit foundation of the juvenile products industry, announced it's launching a Safe Sleep Campaign in partnership with Cribs for Kids, First Candle, and Safe Kids Worldwide. The campaign aims to deliver easy-to-understand,...

at 08:00
MedISAO, an organization composed of members of the medical device manufacturer community dedicated to improving medical device security through education, awareness, and advocacy, announced today its endorsement by the Food and Drug Administration...



News published on and distributed by: